Literature DB >> 28779382

Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.

Manabu Okada1,2, Yoshihiro Tominaga3, Takahisa Hiramitsu3, Toshihiro Ichimori3.   

Abstract

BACKGROUND: We occasionally experience cases of severe secondary hyperparathyroidism (SHPT) that require parathyroidectomy (PTX) despite undergoing short-term renal replacement therapy (RRT). Because the characteristics of such cases have never been discussed, we aimed to elucidate the pathophysiology of severe SHPT after short-term RRT by retrospectively analyzing clinical data.
METHODS: A total of 1013 patients with severe SHPT underwent PTX between January 2007 and April 2016 at Nagoya Daini Red Cross Hospital. Of these patients, 570 underwent RRT for ≥10 years (long RRT group) and 23 for ≤1 year (short RRT group). We retrospectively investigated and compared patient characteristics, preoperative data, subjective symptoms, and bone lesion incidence between the two groups.
RESULTS: A higher proportion of subjects with congenital or hereditary diseases as primary disease for chronic kidney disease (CKD) (21.7% (5/23) vs. 6.3% (36/570); P = 0.016) and longer predialysis period (21.2 ± 14.0 vs. 10.1 ± 9.2 years; P < 0.001) were observed in the short RRT group than in the long RRT group. Furthermore, lower serum calcium and phosphate levels, heavier parathyroid glands, and severe bone lesions were observed in the short RRT group than in the long RRT group.
CONCLUSION: Severe SHPT after short-term RRT appeared to occur because of long-term CKD before initiating RRT. Therefore, treating mineral and bone disorders during the early CKD stage might prevent severe SHPT development before initiating RRT.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28779382     DOI: 10.1007/s00268-017-4164-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  21 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.

Authors: 
Journal:  Ther Apher Dial       Date:  2008-12       Impact factor: 1.762

3.  Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.

Authors:  Masafumi Fukagawa; Keitaro Yokoyama; Fumihiko Koiwa; Masatomo Taniguchi; Tetsuo Shoji; Junichiro James Kazama; Hirotaka Komaba; Ryoichi Ando; Takatoshi Kakuta; Hideki Fujii; Msasaaki Nakayama; Yugo Shibagaki; Seiji Fukumoto; Naohiko Fujii; Motoshi Hattori; Akira Ashida; Kunitoshi Iseki; Takashi Shigematsu; Yusuke Tsukamoto; Yoshiharu Tsubakihara; Tadashi Tomo; Hideki Hirakata; Tadao Akizawa
Journal:  Ther Apher Dial       Date:  2013-06       Impact factor: 1.762

4.  Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.

Authors:  Hitoshi Saito; Kenichiro Kusano; Masahiko Kinosaki; Hirotaka Ito; Michinori Hirata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

Review 5.  The biological action of calcitriol in renal failure.

Authors:  C H Hsu; S R Patel; E W Young; R Vanholder
Journal:  Kidney Int       Date:  1994-09       Impact factor: 10.612

Review 6.  Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

Authors:  G A Block; F K Port
Journal:  Am J Kidney Dis       Date:  2000-06       Impact factor: 8.860

7.  Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D.

Authors:  L Wilson; A Felsenfeld; M K Drezner; F Llach
Journal:  Kidney Int       Date:  1985-03       Impact factor: 10.612

8.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

Authors:  J Silver; T Naveh-Many; H Mayer; H J Schmelzer; M M Popovtzer
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11

10.  Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.

Authors:  O M Gutiérrez; T Isakova; D L Andress; A Levin; M Wolf
Journal:  Kidney Int       Date:  2008-02-06       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.